President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes
Read MorePresident and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.
Read MorePlant-inspired biopharmaceutical company signs leading contract research organization to help with a go-to-market strategy for its cannabinoid-containing therapy for COVID-related cytokine release syndrome.
Read MoreOn March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' proprietary, time-released, oral nanoparticle technology improved the efficacy of cannabis-based terpenes in modulating a known pain receptor in this study.
Read MoreThis new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
Read MoreGb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
Read MoreBiopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships
Read MoreThe biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
Read MoreBased on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.
Read MoreHighlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.
Read MoreGB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain inspired by a family of pepper plants used in traditional medicines around the world.
Read More